论文部分内容阅读
目的分析研究缬沙坦联合美托洛尔治疗慢性充血性心力衰竭患者的临床疗效及安全性。方法选择2010年1月至2011年1月期间在我院治疗的106例慢性充血性心力衰竭患者,将106例患者随机分成治疗组56例和对照组50例,对照组给予内科常规治疗,包括强心药、利尿剂、硝酸酯类等。治疗组在对照组治疗基础上给予缬沙坦联合美托洛尔治疗,两组患者均治疗6个月,治疗后评定两组患者的临床治疗效果。结果用药6个月后,治疗组总有效率为91.07%,对照组总有效率为78.00%,两组比较差异有统计学意义(P<0.05),治疗组反映心室重构指标、左室收缩功能及舒张功能指标均有明显改善,而对照组改善不明显,两组比较差异有统计学意义(P<0.05)。结论缬沙坦联合美托洛尔治疗慢性充血性心力衰竭,可改善患者的心功能,疗效优于常规治疗,值得临床上推广应用。
Objective To study the clinical efficacy and safety of valsartan combined with metoprolol in the treatment of patients with chronic congestive heart failure. Methods A total of 106 patients with chronic congestive heart failure who were treated in our hospital from January 2010 to January 2011 were randomly divided into treatment group (56 cases) and control group (50 cases). The control group was given conventional medical treatment including Cardiac drugs, diuretics, nitrates and so on. The treatment group was given valsartan combined with metoprolol on the basis of the control group. The patients in both groups were treated for 6 months. The clinical effects of the two groups were evaluated after treatment. Results After 6 months of treatment, the total effective rate was 91.07% in the treatment group and 78.00% in the control group. There was significant difference between the two groups (P <0.05). The treatment group showed ventricular remodeling, left ventricular systolic Function and diastolic function index were significantly improved, while the control group did not improve significantly, the difference between the two groups was statistically significant (P <0.05). Conclusion Valsartan combined with metoprolol in the treatment of chronic congestive heart failure can improve the patient’s cardiac function, the curative effect is better than the conventional treatment, which is worth popularizing and clinical application.